March 24, 2011

CNBC

TranS1 gets FDA approval for product

NEW YORK - Medical device maker TranS1 Inc. said Thursday it received Food and Drug Administration clearance for a spinal implant system.

Shares surged $1.13, or 35 percent, to $4.39 in premarket trading.

TranS1 said it received clearance for the "AxiaLIF 1L+" product line, an instrumentation and implant system for L5-S1 lumbar fusion.

The company said the system "represents the next generation of the original AxiaLIF 1L system first launched in 2005."